

Date: January 20, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Corrigendum to the Media Release submitted with the Outcome of the Board Meeting dated January 20, 2026

Dear Sir/Madam,

This is with reference to the Media Release submitted along with the Outcome of Board Meeting held on January 20, 2026 for approval of Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. Post submission of the Outcome, it has come to our notice that inadvertently in Annexure B i.e. Media Release, there was a minor typing error.

Further, in order to set the records right for all the stakeholders, we enclose herewith a copy of revised Media Release as **Annexure-A**. Furthermore, since the Media Release forms the part of the Outcome of the Board Meeting held on January 20, 2026 filed with the stock exchanges. The said Outcome shall always be read in conjunction with this Corrigendum.

We assure to take due care in future and sincerely regret the inconvenience caused.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosure: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com




W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED




Strong Financial & Operational Performance for Q3 & 9M FY26

Ahmedabad, Gujarat, 20th January 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its un-audited Financial Results for the 3rd Quarter and nine-months year ended 31st December 2025.

Q3FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS

INCOME* Rs. 175 Crs.  +64% <small>Y-o-Y for Q3FY26</small>	EBITDA Rs. 54 Crs.  +86% <small>Y-o-Y for Q3FY26</small>	PROFIT AFTER TAX Rs. 34 Crs.  +105% <small>Y-o-Y for Q3FY26</small>
--	---	---

9M FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS

INCOME* Rs. 474 Crs.  +65% <small>Y-o-Y for 9MFY26</small>	EBITDA Rs. 138 Crs.  +87% <small>Y-o-Y for 9MFY26</small>	PROFIT AFTER TAX Rs. 85 Crs.  +110% <small>Y-o-Y for 9MFY26</small>
--	--	---

KEY HIGHLIGHTS for Q3 & 9M FY26

- Cash Flow from Operations for Q3FY26 stood **at ~Rs. 19 crs** & for 9MFY26 it stood at **~Rs. 51 crs**, significant growth over last year. Our EBITDA-to-Operating Cash Flow conversion has improved
- **46 approved ANDAs covering 137 strengths**, with over 100 strengths yet to be launched and 22 additional ANDAs under development with 50+ strengths, providing strong growth visibility for our regulated business in the coming years
- **Highest-ever Revenue and EBITDA in Emerging Markets business in Q3FY26** – Revenue for Emerging markets **grew by ~48%** for Q3FY26 on a Y-o-Y basis. EBITDA margin for emerging markets stood at ~13% for Q3FY26 compared to ~1% in Q3FY25, **a significant jump of 1,200 bps.**
- **Update on Acquisition of Apnar Pharmaceuticals** – Phase 1 - **75% stake acquisition completed**; Phase 2 – Balance 25% to be completed by Q2FY27. Out of 5 approved ANDAs, **3 ANDAs to be launched in Q4FY26**, expected to generate positive cash flow. **Business integration and scale-up happening faster than anticipated.**


* Total Income includes Revenue from Operations & Other Operating Income

Q3 & 9M FY26 OPERATIONAL & FINANCIAL HIGHLIGHTS


Income Breakup

■ Regulated Markets ■ Emerging Markets ■ Others


Q3 FY25




Q3FY26




9M FY25




9M FY26




Regulated Markets



Emerging Markets



Others



Regulated Markets

- Q3 FY26 Revenue stood at Rs. 112.7 crs, **a growth of 60.5% Y-o-Y**. EBITDA Margin stood at 40%
- 9M FY26 Revenue stood at Rs. 309.6 crs, **a growth of 71.5% Y-o-Y**. EBITDA Margin stood at 40%.

Emerging Markets

- Revenue for Q3 & 9M FY26 stood at Rs. 38.4 crs & Rs 61 crs respectively.
- EBITDA Margin for Q3 & 9M FY26 stood at 13% & 9%.

Product Portfolio in Regulated Markets;

- Own ANDAs
 - Approved Portfolio - **46** ANDAs with **137** Strengths
 - Commercialized Portfolio – **18** ANDAs with **35** Strengths
 - Pipeline Products – **22** ANDAs with **52** Strengths
- CDMO/ CMO
 - Commercialized Product Portfolio – 16 products with 34 strengths
 - Pipeline Products – 16 products with 57 strengths

For the emerging markets currently, company has;

- 450 Approved products
- 858 products under registration
- Presence across more than 40 countries

Commenting on the results, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“Continuing our strong momentum, we delivered a robust performance in Q3FY26, with Revenue growing by 64% and Profit after Tax growing by 86% Y-o-Y.

In the Regulated Markets, we launched two new ANDAs with 3 strengths during the quarter. We have 28 approved ANDAs available for launch. Additionally, we have 22 more molecules, involving 50+ strengths, at different stages of development. This gives us a healthy pipeline of products which are expected to be rolled out over the coming quarters.

We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharma. We have completed acquisition of 75% stake, with the balance 25% expected to be completed by Q2 FY27. The integration and scale-up of the Apnar Pharma business is happening faster than expected. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth.

Our Emerging Markets product portfolio continued to expand. With the shift towards niche products, we are now at mid-teens EBITDA Margin. We achieved our highest-ever quarterly Revenue and EBITDA in Emerging Markets in Q3 FY26. Importantly, the business is now cash flow positive.

The Branded Generics business is seeing significant growth, with revenue growing more than six-fold Y-o-Y in Q3FY26. Strong product acceptance and customer adoption are driving this momentum. We are now approved and supplying to multiple large hospital chains across India.

All in all, we have delivered a strong performance in the quarter and nine-months and remain on track to deliver on our full year guidance. We will continue to drive the business on 4 key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets; and (iv) Scale-up of Branded Generics business in India.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio in Regulated Markets includes 46 own ANDAs with 137 strengths and 16 CMO/CDMO commercial products with 34 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 450 product registrations and over 850 products under application. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant & 2 in Gujarat, India. One of the facilities in Gujarat is USFDA approved while the other is approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 4 R&D sites (1 in the USA and 3 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899